(S)-tert-butyl 4-methyl-4-(3-methylpiperazin-1-yl)piperidine-1-carboxylate
- $241 - $1050
- Product name: (S)-tert-butyl 4-methyl-4-(3-methylpiperazin-1-yl)piperidine-1-carboxylate
- CAS: 306296-78-6
- MF: C16H31N3O2
- MW: 297.44
- EINECS:
- MDL Number:MFCD19441363
- Synonyms:(S)-tert-butyl 4-methyl-4-(3-methylpiperazin-1-yl)piperidine-1-carboxylate;[4-(2,3-Dihydro-1,4-benzodioxin-6-yl)tetrahydro-2H-pyran-4-yl]methanamine;1-Piperidinecarboxylic acid, 4-methyl-4-[(3S)-3-methyl-1-piperazinyl]-, 1,1-dimethylethyl ester;Tert-butyl (S)-4-methyl-4-(3-methylpiperazin-1-yl)piperidine-1-carboxylate
3 prices
Selected condition:
Brand
- Alichem
- Sigma-Aldrich
Package
- 5mg
- 250mg
- 1g
- ManufacturerAlichem
- Product number306296786
- Product description(S)-tert-Butyl4-methyl-4-(3-methylpiperazin-1-yl)piperidine-1-carboxylate
- Packaging250mg
- Price$416
- Updated2021-12-16
- Buy
- ManufacturerAlichem
- Product number306296786
- Product description(S)-tert-Butyl4-methyl-4-(3-methylpiperazin-1-yl)piperidine-1-carboxylate
- Packaging1g
- Price$1050
- Updated2021-12-16
- Buy
- ManufacturerSigma-Aldrich
- Product numberPH017132
- Product description[4-(2,3-Dihydro-1,4-benzodioxin-6-yl)tetrahydro-2H-pyran-4-yl]methanamine AldrichCPR
- Packaging5mg
- Price$241
- Updated2023-01-07
- Buy
Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
---|---|---|---|---|---|---|
Alichem | 306296786 | (S)-tert-Butyl4-methyl-4-(3-methylpiperazin-1-yl)piperidine-1-carboxylate | 250mg | $416 | 2021-12-16 | Buy |
Alichem | 306296786 | (S)-tert-Butyl4-methyl-4-(3-methylpiperazin-1-yl)piperidine-1-carboxylate | 1g | $1050 | 2021-12-16 | Buy |
Sigma-Aldrich | PH017132 | [4-(2,3-Dihydro-1,4-benzodioxin-6-yl)tetrahydro-2H-pyran-4-yl]methanamine AldrichCPR | 5mg | $241 | 2023-01-07 | Buy |
Properties
Safety Information
Symbol(GHS): | ||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Signal word: | Warning | |||||||||||||||||||||
Hazard statements: |
|
|||||||||||||||||||||
Precautionary statements: |
|